Roche began shipping Axelios 1 commercially, positioning its next-generation sequencing platform as a direct challenge to Illumina’s installed base. The company said initial distribution will focus on North America, Europe, and Asia-Pacific. Roche framed Axelios 1 around improvements in accuracy, speed, flexibility, scalability, and cost efficiency—features aimed at addressing bottlenecks that can slow genomic workflows and increase run costs. The launch is a reminder that platform competition in genomics remains a key enabler for downstream diagnostics and research-scale sequencing adoption.